WHO ICTRP trial
A Study to evaluate safety, tolerability and preliminary efficacy of FP-1305 in…
EUCTR2018-002732-24-FI · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2018-002732-24-FI |
|---|---|
| Public title | A Study to evaluate safety, tolerability and preliminary efficacy of FP-1305 in cancer patients |
| Scientific title | A Phase I/II Open–Label, Three-Part, Dose-Finding and Separate Cohort Expansion Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Repeated Doses of CLEVER-1 Antibody FP-1305, in Subjects with Advanced Solid Tumours - MATINS |
| Primary sponsor | Faron Pharmaceuticals Ltd |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): yes Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | France;United States;Finland;Spain;Netherlands;Germany;United Kingdom |
| Conditions | Selected solid tumours; - cutaneous melanoma - pancreatic ductal adenocarcinoma - ovarian cancer - colorectal adenocarcinoma - hepatocellular carcinoma - gallbladder cancer and cholangiocarcinoma - uveal melanoma - gastric adenocarcinoma… |
| Interventions | Product Code: FP-1305 Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Bexmarilimab Current Sponsor code: FP-1305 Other descriptive name: CLEVER-1 ANTIBODY Concentration unit: mg/ml milligram(s)/millilitre… |
| Registration date | Sep 27, 2018 |
| Target size | 700 |
| Secondary IDs | FP2CLI001;NCT03733990 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: